Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws

Authors

Christopher M. Holman, University of Missouri - Kansas City, School of LawFollow

Publication Date

10-2023

Document Type

Article

Publication Title

Biotechnology Law Report

Volume

42

Issue

5

Recommended Citation

Christopher M. Holman, Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws, 42 Biotechnology Law Report 230 (2023).
Available at: https://irlaw.umkc.edu/faculty_works/970